Introduction: the versatile *Xenopus* system applied to oncology {#s0005}
================================================================

Since the 1950s, *Xenopus laevis* has become the most widely used amphibian research organism ([@bib96]), with unique versatility in providing a range of both *in vitro* and *in vivo* models that are rapid, accessible and easily manipulated. The collective use of *Xenopus* oocytes, egg extracts, cell cultures and whole embryos in cancer research has made valuable contributions to understanding tumour biology, as well as improving therapeutic options in both diagnostics and chemotherapeutics.

Modelling with *Xenopus* eggs and cleavage stage embryos {#s0010}
========================================================

Investigating cell cycle mechanisms {#s0015}
-----------------------------------

The events and regulatory mechanisms governing the cell cycle are essential for regulation of cellular proliferation and genomic stability, and several checkpoints exist to ensure successful completion of one stage before progression to the next ([@bib45]). Not only are pathways involved in cell cycle control frequently mutated in cancer, but deregulation of the cell cycle checkpoints promotes further acquisition of DNA mutations that can progress a cell down the route to metastasis ([@bib58]).

*Xenopus* oocytes, eggs and early embryos have served as fundamental experimental systems in which to elucidate the mechanisms of the cell cycle and the coordination of the cell cycle and differentiation during development (e.g. [@bib3], [@bib33], [@bib34], [@bib71]; for a review, see [@bib84]). Large volumes of extracts can be prepared from eggs and oocytes by centrifugation, and these contain vast arrays of proteins that enable reconstitution of cell cycle events, nuclear transportation, microtubule polymerisation and apoptosis (e.g. [@bib15], [@bib61], [@bib62], [@bib76], [@bib129], [@bib27]). Moreover, the cell-free nature of the extract system means the molecular machinery involved in these processes can be probed by manipulation of extracts with immune-depletion or neutralisation of an endogenous protein of interest, followed by subsequent rescue by addition of recombinant protein (e.g. [@bib97], [@bib127]). Similar approaches allow the identification of endogenous targets of drug compounds that influence cell cycle kinetics ([@bib91]). Extracts can also be prepared to represent different phases of the cell cycle, and these, for example, can be used to study changes in protein stability during the cell cycle ([@bib69], [@bib109]).

Given this impressive versatility, it is not surprising that the *Xenopus* egg extract system can also be applied to study the molecular derangements of cell cycle events that promote or accompany neoplastic transformation. In particular, biochemical investigation of the control of DNA replication, of DNA repair and of checkpoint control has been extensive. Plasmid replication can be studied in "nucleus-free" systems, but classic DNA replication experiments involve the addition of demembranated sperm chromatin to unfertilised egg extracts, which results in the formation of nuclei that undergo semi-conservative, cell-cycle regulated DNA replication ([@bib63], [@bib97]). Using this system, work has characterised the biochemical aspects of control of the replication process ([@bib14], [@bib29]) and DNA replication fork stability ([@bib46]). Addition of linear DNA fragments to *Xenopus* egg extracts mimics the effects of double strand breaks in genomic DNA, enabling study of DNA damage checkpoints in a cell-free model ([@bib119], [@bib128]). Detailed methods are also described for studying mitotic spindle assembly and checkpoints ([@bib28]), and many mitotic spindle factors that are altered in cancer are conserved in *Xenopus* ([@bib24], [@bib52]).

However, *Xenopus* is not limited to *in vitro* investigation of cell cycle function; the developing *Xenopus* embryo also presents an interesting *in vivo* system to study regulation of proliferation ([@bib120]) particularly in view of the changes in the cell cycle regulation during early development ([@bib94]). The first 12 embryonic cell cycles occur rapidly and synchronously, driven by stockpiles of maternal proteins, and alternating between DNA replication in S phase and cell division in M phase ([@bib84]). The mid-blastula transition (MBT) marks the onset of zygotic transcription, after which cell cycles become asynchronous and gradually lengthen with incorporation of G1 and G2 phases ([@bib74], [@bib75]). Furthermore, the cell cycle is intimately linked with the process of differentiation during development (for example [@bib19], [@bib107]) and for review see ([@bib44]). As well as providing a platform for studying *in vivo* mechanisms of cell cycle control, the ease of experimental manipulation lends itself to investigate the mechanistic links between proliferation and differentiation, links that are often perturbed in cancer ([@bib105], [@bib86], [@bib3], [@bib49]).

Using *Xenopus* oocytes to model cancer cell signalling {#s0020}
-------------------------------------------------------

Distinct from studying somatic cell division, the *Xenopus* oocyte has also proven to be a highly versatile and powerful tool for investigating signalling cascades and their effects on cell growth. The large size of the oocyte enables microinjection of substances without disturbance of the normal physiology ([@bib120]) and components of signalling paths can be studied in isolation from the complex milieu of growth signals that complicate the endogenous tumour environment ([@bib18], [@bib16]). For example, tumour-secreted fibroblast growth factor 1 (FGF1) and tumour-expression of its receptor FGFR1 are involved in the proliferation of oestrogen-negative human breast cancer cells ([@bib18]). *Xenopus* oocytes lack endogenous FGFRs, enabling the study of FGFR1 receptors derived from malignant breast cancer cell lines following oocyte over-expression. Stimulation of the exogenous receptors by *in vitro* applied FGF ligands triggers oocyte maturation and passage through the G2/M transition that serves as a read-out of FGF signal transduction ([@bib18]). This model has been used to characterise the downstream components responsible for this transition into M phase ([@bib16]), and also to identify potential pharmacological inhibitors of this pathway ([@bib18]).

*Xenopus* oocytes and cancer metabolism {#s0025}
---------------------------------------

The *Xenopus* oocyte has also found favour in the studies of cancer metabolism. In this respect, the oocyte has the advantage of being large enough to enable biochemical measurements in a single cell, and allow microinjection of compounds that would otherwise require the use of harsh permeabilisation techniques in heterogenous populations of cells ([@bib103]). Indeed, the *Xenopus* oocyte has been described as a "living test-tube" in which to study metabolic regulation ([@bib103]). It is perhaps not surprising therefore, that the oocyte has also formed an *in vitro* model for the study of deranged metabolism in cancer cells. A detailed discussion is beyond the scope of this review, but interestingly, the metabolic phenotypes and intermediary pathways seen in cancer cells are similar to those found in the *Xenopus* oocyte, enabling the extract system to model the relationship between cancer metabolism and cell death ([@bib27], [@bib31]) and for review see ([@bib76]). Furthermore, over-expression of tumour-associated signalling proteins and nutrient transporters in *Xenopus* oocytes can serve as a model to study alterations in glucose handling by tumour cells, (for example [@bib81]). Overall, these *Xenopus* assays have already contributed to cancer metabolomics but also provide viable models for future investigations into therapeutic targeting of abnormal cancer metabolism.

*Xenopus* embryogenesis: a developmental model for cancer studies {#s0030}
=================================================================

Parallels between early development and tumourigenesis {#s0035}
------------------------------------------------------

From as early as the 1890s, parallels were drawn between the development of the early embryo and the pathological development of neoplasia. Over a century of research has built on these foundations and a body of literature now documents the similarities in terms of epigenetic signatures, transcriptomes, proteomes, metabolism and cell behaviour ([@bib67], [@bib114], [@bib121], [@bib124]). Signalling pathways that are critical during embryonic development (such as Sonic Hedgehog, Wnt, Notch and Bone Morphogenetic Proteins) are also instrumental in tumour progression to a metastatic phenotype ([@bib9]). Similarly, high rates of cell proliferation are seen in both embryonic and tumour cells, in part due to the activity of pro-proliferative signalling pathways and transcription factors ([@bib67]). Therefore cancer can perhaps be viewed as an inappropriate re-activation or alteration of normal embryonic growth pathways ([@bib83]), or perhaps a disorder of cellular differentiation, where cells instead remain locked in the proliferative mode prior to cell fate determination, as seen in some induced tumour models ([@bib113]). In this respect, characterisation of normal developmental pathways can assist in understanding the derangements that occur during oncogenesis, and also aid in the identification of potential novel diagnostic or therapeutic targets. Acknowledged benefits of the *Xenopus* system include the accessibility of the early developmental stages and the ease of targeted expression due to accurate fate maps. These enable *Xenopus* to form an instrumental model for developmental biologists and oncologists alike ([@bib112]).

Characterising oncogenes: induced tumours in developing *Xenopus* embryos {#s0040}
-------------------------------------------------------------------------

In the late 1990s, three independent groups reported induced tumour phenotypes in developing *Xenopus* embryos. This was achieved either through over-expression of oncogenes such as Gli1 ([@bib25]) or Xrel3 ([@bib126]), or through inhibition of tumour suppressor protein p53 ([@bib113]). Histologically these induced tumours contain poorly differentiated cells with abnormal nuclear morphologies ([@bib112]), and in the case of Gli1-induced epidermal growths, the molecular phenotype suggests that these tadpole tumours may be equivalent of human basal cell carcinomas ([@bib25]). Subsequent work has referred to these lesions as induced tumour-like structures (ITLS), characterised by disorganised undifferentiated cells with increased proliferation and abnormal nuclear size, invasive behaviour and the ability to stimulate angiogenesis ([@bib23]). Thus, from this early work, *Xenopus* has gained increasing credibility as a valid *in vivo* model for various forms of human malignancy, in addition to the potential for functional screening for therapeutic agents that may diminish the induced tumour phenotype ([@bib112]).

Interestingly, the early work that uncovered a tumourigenic phenotype from inhibition of p53 in *Xenopus* embryos, was originally undertaken to characterise the role of p53 during early embryogenesis. *Xenopus* was used as a rapid developmental model to minimise the effects of genetic instability resulting from p53 knockdown ([@bib113]). Tumour cells divide normally, but fail to undergo the normal differentiation process ([@bib113]), and this may therefore support the view that cancer is sometimes a failure of differentiation rather than abnormal proliferation *per se*. Similarly, the dose-dependent tumourigenic phenotype from over-expression of Xrel3 was realised following identification of this novel c-rel homologue during early development; the authors suggest that the endogenous Xrel3 function may be in the cellular proliferation *versus* differentiation decision ([@bib126]).

These examples highlight the importance of examining the parallels between development and tumourigenesis, not only to uncover cellular functions for known oncogenes, but also to assist identification of potential oncogenic activity in genes with a known developmental function. In this way, viral and cellular proto-oncogenes have been found to have endogenous developmental roles, for example as p21^ras^ ([@bib118]). Conversely, human homologues of developmental regulators have been identified as having key oncogenic or tumour suppressor roles. For example, the presence of anterior gradient 2 (AGR2), a human homologue of the *Xenopus* cement-gland specific gene, correlates with and can even confer metastatic phenotype in human breast carcinomas ([@bib64]), whereas VentX, the human homologue of *Xenopus* homeobox transcription factor Xom, induces senescence in osteosarcoma and lymphoblastic leukaemia cell lines ([@bib122]).

Developing *Xenopus* embryos can also be used to probe the molecular mechanisms of oncogenes in signalling pathways. For example, HGF/SF (hepatocyte growth factor scatter factor) is a ligand for activation of the Met tyrosine kinase receptor, and aberrant activity of this pathway contributes to tumour cell invasion and metastasis in a number of human cancers ([@bib51]). Over-expression of oncogenic mutant forms of Met receptor in *Xenopus* embryos leads to the formation of ectopic morphogenic structures, thereby providing a rapid *in vivo* assay of tumorigenesis. This model has enabled identification of downstream components that contribute to the oncogenic deregulation of this pathway ([@bib51]).

In recent years, several powerful genome editing techniques have become available for use in *Xenopus*, opening the way to advanced genetic modifications that are already established in murine models; these include the use of zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and CRISPR/Cas system, as reviewed in ([@bib96]). Combined with the expanding number of transgenic frog lines, it will surely not be long before transgenic models are generated to model various aspects of specific mammalian cancers. Such a technique has recently been employed to produce a transgenic *Xenopus* model to study lymphangiogenesis ([@bib77], [@bib78]). With an increasingly appreciation of the underlying genetic derangements in specific types of human cancers, this will be an interesting avenue to pursue with *Xenopus* transgenics.

Wnt signalling in development and cancer {#s0045}
----------------------------------------

The Wnt signalling pathway has vital roles at different stages in embryonic development, regulating processes including cell proliferation and cell fate specification, cell migration and polarity, and body axis formation ([@bib48]). Yet aberrant activity of Wnt ligands and their downstream effectors are also important for tumour initiation, growth, progression and metastasis, with acknowledged roles in breast, prostate, gastro-intestinal, liver and lung cancers, in addition to melanoma and bone metastasis ([@bib123], [@bib102]).

Different intracellular signalling cascades can be activated downstream of the active Wnt-Frizzled receptor, in part due to the diversity of Wnt ligand families that primarily activate one or more pathways and have conflicting effects on cell behaviour ([@bib38]). Canonical Wnt signalling refers to activation of the Wnt/β-catenin pathway by Wnt-1 family ligands. Non-canonical Wnt pathways include activation of the Wnt/Ca^2+^ pathway and the Wnt/planar cell polarity (PCP) pathway, usually by Wnt-5A family members ([@bib54]). These signalling cascades are highly conserved in evolution, and *Xenopus* has provided rapid assay methods to investigate various aspects of pathway regulation. The most well-established assay for canonical Wnt signalling is the *Xenopus* axis duplication assay ([Fig. 1](#f0005){ref-type="fig"}), but *Xenopus* oocytes can also be used as a secretory system to release human Wnt ligands for a variety of paracrine assays ([@bib21]), and CaMKII activity in *Xenopus* embryos can provide a measure of non-canonical Wnt signalling ([@bib56]).

Given the instrumental role that aberrant Wnt signalling can have in cancer progression, inhibition of this pathway has proved to be an attractive chemotherapeutic target, and the *Xenopus* axis duplication assay is a highly efficient screen for potential candidate inhibitors (see below and [@bib55]). Endogenously, β-catenin is stabilised on the prospective dorsal side of the embryo during the first cell cycle, due to the cortical rotation that follows sperm entry. This leads to activation of transforming growth factor-β (TGFβ) family members *siamois* and *Xenopus nodal-related 3* (*Xnr-3*), that promote formation of dorsal structures. Injection of mRNA encoding Wnt ligand or β-catenin into the marginal zone of a ventral blastomere of a 4-cell stage *Xenopus* embryo results in duplication of the body axis, with results visible from neurula stages, just 36 h after injection ([@bib55]).

Epithelial to mesenchymal transitions in development and cancer {#s0050}
---------------------------------------------------------------

One of the most striking examples of the similarity between embryonic development and malignant behaviour is presented by the morphological changes that accompany epithelial to mesenchymal transitions (EMT) in development and cancer. These EMT and mesenchymal to epithelial (MET) events are fundamental changes of cell shape, polarity and migration that are central but transient events during embryogenesis, and are responsible for processes such as blastula formation, gastrulation, neural crest formation, somitogenesis and cardiac morphogenesis; for detailed reviews see ([@bib1], [@bib2], [@bib53], [@bib73], [@bib99], [@bib100]). These transitions may be complete or partial during embryogenesis, but nevertheless they provide essential insights into behaviours that can be inappropriately reactivated during tumour progression, while EMT is a key event in malignant invasion ([@bib106]). Indeed, genes that have pivotal roles in EMT events during embryogenesis are often mutated or aberrantly expressed in cancer cells ([@bib60], [@bib68], [@bib73], [@bib98], [@bib106], [@bib125]); this underscores the importance of understanding the developmental regulation of this process.

In this way, study of embryonic neural crest cells is often used as an *in vivo* and *in vitro* model of EMT, with neural crest cells displaying the activity of signalling paths, transcription factors, cell-adhesion changes and matrix remodelling that are similarly responsible for invasion and metastasis of epithelial tumours, comprehensively reviewed in ([@bib99]). This developmental approach has highlighted the importance of the bHLH protein Twist, for both embryonic and cancer-associated EMT ([@bib106], [@bib125]), with *Xenopus* neural crest formation serving as a model to investigate the role and regulation of Twist ([@bib60]). Twist is similarly considered a master regulator of EMT in malignant breast cancer, highly expressed in tumour cells yet rarely expressed in normal adult cells, therefore generating interest as a potential therapeutic target ([@bib35]). Additionally, the study of epithelial cell behaviour can also be conducted using the established *Xenopus* A6 cell line. These cells are derived from normal *Xenopus* kidney tissue, and behave *in vitro* as typical polarised epithelial monolayers, and therefore are suitable for investigating epithelial cell migration and morphogenesis ([@bib70]).

Taken together, these examples highlight the complementary fields of developmental biology and oncology, and how advances in one area can prove directly relevant to understanding the molecular mechanisms in the other. Signalling pathways and morphogenic events in development are highly conserved between species; *Xenopus* is therefore a highly pertinent model for elucidating these critical components.

Spontaneous tumours and tumour resistance in *Xenopus* {#s0055}
======================================================

Spontaneous tumours in amphibians are rare ([@bib92]), but even this phenomenon can nevertheless make a valuable contribution to mammalian cancer biology. The multi-step process through which a cell progresses in order to gain a fully malignant phenotype has been well characterised in mammals, both at cellular and genetic levels ([@bib42], [@bib43]). What are less well characterised are the complex and multiple interactions that exist between tumour cells and the host immune system. In one respect, "cancer immune-surveillance" describes the detection and destruction of tumour cells by the host immune system. Conversely, the immune system can exert a selection pressure on the heterogenous tumour cell population, leading to the persistence and growth of resistant or less immunogenic cells in the process of "immune-editing" ([@bib17]). *Xenopus* has played a key role in both *in vitro* and *in vivo* studies of anti-tumour immune responses, providing evidence for both of these mechanisms ([@bib37]).

Spontaneous tumours {#s0060}
-------------------

Despite the relatively lower incidence of spontaneous tumours in *Xenopus* compared to mammalian models, several neoplastic conditions have been described, including hepatomas ([@bib87]), ovarian tumours ([@bib37]), and thyroid-containing teratomas ([@bib22]). The definition of neoplasia in *Xenopus* has come under some scrutiny, as the original report of a virally-induced and highly malignant lymphosarcoma ([@bib10]) was subsequently shown to be a transmissible (but not transplantable) infectious granuloma ([@bib8]), caused by myocobacterium marinum ([@bib7]). However, the most experimentally useful tumours have proven to be the thymic lymphomas, first recorded in the early 1990s and subsequently described in 4 genetically different adult *Xenopus* frogs at the Basel Institute of Immunology ([@bib30], [@bib90]), and one at the Tulane University *Xenopus* colony ([@bib32]). The tumours fulfil the criteria for spontaneous neoplasia, propagating in isogenic animals, being rejected in allogenic animals and enabling the derivation of stable lymphoid cell lines that can be cloned from single cells and cultured indefinitely ([@bib30]). Characteristics of the 5 lymphoid cell lines (B3B7, 15/40, 15/0, ff-2 and ff2.64) are comprehensively reviewed elsewhere ([@bib88]), and while all are mixed T/B cell phenotypes, they appear to arise from independent oncogenic events ([@bib90]). These cell lines also demonstrate aneuploidy with marked genetic instability in addition to up-regulation of c-myc ([@bib37]), thus illustrating their relevance as *in vitro* and *in vivo* models of mammalian cancer biology.

Tumour resistance in amphibians {#s0065}
-------------------------------

The relative resistance of *Xenopus* (and other amphibians) to spontaneous and transplanted tumours has provided an intriguing model to study the mechanisms of tumour immunity. A range of developmental and physiological features in amphibians may contribute to their relative tumour resistance, as reviewed in ([@bib92]), and metamorphosis provides a particularly interesting evolutionary perspective with respect to differences between the more primitive larval immune system and that found in the adult ([@bib88]). The stable lymphoid cell lines derived from the different thymic tumours have been used in transplantation studies to determine components of the laval or adult immune system that are required to afford tumour immunity ([@bib30], [@bib89]). Together, these studies have demonstrated a conserved and critical function of T cells in tumour immunity, directed against tumour-specific antigens ([@bib89]). Furthermore, recent work has identified molecular mechanisms involving expression of class Ib MHC molecules that may be responsible for immune evasion by the 15/0 tumour cells ([@bib47]). In combination, these studies support both the immune-surveillance and immune-editing hypotheses, and it will now be interesting to translate these findings to comparable mammalian tumour models.

*Xenopus* contributions to translational medicine: insights that may improve clinical approaches to cancer {#s0070}
==========================================================================================================

From the discussion above, the *Xenopus* system has clear relevance to our understanding of cancer aetiology, biology and physiology, and from these studies, future therapeutic targets may be identified. This final section focuses more specifically on the application of the *Xenopus* system to clinical practice, largely in the form of developing chemotherapeutic agents, but we finish with a novel and exciting avenue of *Xenopus* research into epigenetic reprogramming of cancer cells.

Chemotherapeutic drug discovery {#s0075}
-------------------------------

The contributions of the *Xenopus* system to drug discovery and development again emphasises the versatility of this system, with oocytes, isolated embryonic cells and whole embryo models available to researchers. *Xenopus* oocytes have served as a fundamental tool in pharmaceutical research, from preliminary drug candidate screening ([@bib57], [@bib59]) through to characterisation of drug pharmacodynamics ([@bib117]) and drug pharmacokinetics and tumour targeting ([@bib6]). This model has been used extensively to study the electrophysiology of exogenous ion channels, and the activity of compounds to modulate channel function in the search for new chemotherapeutics, for example ([@bib57]). Injection of *in vitro* transcribed cRNAs into oocytes can produce functional channel expression within 2 days, and the large size of the oocyte is readily amendable to patch clamp experiments or 2 electrode voltage clamping ([@bib65], [@bib82]). This approach can also aid advances in diagnostic imaging, for example in characterising the kinetics of radiotracers used in PET (positron emission tomography) scans for visualising prostate cancer ([@bib79]).

Secondly, isolated embryonic cells provide a rapid and efficient model for assaying the anti-proliferative effects of potential chemotherapeutics ([@bib72]), and the utility of the whole embryo axis duplication assay was mentioned earlier as a vital screen for compounds affecting the canonical Wnt signalling path ([@bib55]). These studies have led to identification of candidate drugs that may assist in the future treatment of several human cancers, particularly colon cancer ([@bib102], [@bib110], [@bib111]) and glioblastoma ([@bib26]). Additionally, older tadpole stage embryos can also provide an assay method to easily assess the effects of compounds on organ development; progressive transparency acquired during tadpole stages enables direct visualisation of a range of organs and tissues. This has been utilised to identify chemicals that suppress pigment cell development with potential use in treatment of melanoma, and compounds with anti-angiogenic or anti-lymphangiogenic activity that may have relevance to inhibit tumour pathogenesis ([@bib96]).

*Xenopus* extracts and epigenetic reprogramming {#s0080}
-----------------------------------------------

Another interesting recent field of study has involved the possibility of reprogramming cancer cells in order to reverse the epigenetic changes that have resulted in gene activation or silencing at certain critical gene promoters. From the pioneering nuclear transfer experiments of John Gurdon and colleagues ([@bib39]), the field of cellular reprogramming has advanced, with hopes of application to disease modelling and ethically acceptable forms of regenerative medicine. Indeed, several techniques are now recognised for directly or indirectly converting one somatic cell type to another, but a caveat remains regarding aberrant reprogramming that can be tumorigenic ([@bib36]). Significant investment is being made to define cocktails of mammalian transcription factors that can direct lineage conversion on over-expression ([@bib66], [@bib4]), but *Xenopus* also presents experimental systems for reprogramming by nuclear transfer ([@bib41]).

In addition to the established genetic mutations that have been characterised in various human cancers, abnormal epigenetic alterations have been ascribed roles in the pathogenesis of several different human malignancies ([@bib93]). Epigenetics refers to stable and heritable patterns of gene expression that contribute to cellular phenotype, caused by mechanisms other than changes in primary DNA nucleotide sequences ([@bib40]). However, epigenetic chromatin modifications are reversible and therefore attractive targets to counteract malignancy ([@bib5]). Extracts prepared from ovarian prophase axolotl oocytes have previously been shown to remodel somatic mammalian cell chromatin ([@bib13]), and this work has since been extended to demonstrate reprogramming of breast cancer cell lines by axolotl and *Xenopus* oocyte extracts. Mechanistically, reactivation of silenced tumour suppressor genes is achieved through promoter demethylation and histone remodelling, and phenotypically this is associated with long term suppression of breast cancer cell tumourigenicity ([@bib5]). Furthermore, this phenomenon has similarly been demonstrated using bovine oocyte extracts to reprogram human lung cancer cells, reactivating silenced tumour suppressor genes without up-regulation of pluripotency-associated genes ([@bib115], [@bib116])

The application of this technology to cancer studies will be more as a method to study the epigenetic contribution to tumorigenesis, rather than a treatment *per se*. But future work may uncover mechanisms that can be therapeutically targeted to achieve a reversal of the epigenetic alteration, thus ameliorating the malignant phenotype.

Concluding remarks: *Xenopus* as a complimentary system to mouse and human cancer models {#s0085}
========================================================================================

The preceding discussion has revealed the large contribution that *Xenopus* has, and continues to make to mammalian oncology. From an understanding of the basics of cell division and differentiation, through oncogene function and cancer aetiology, to characterisation of the molecular pathogenesis and metabolic derangements of cancer, these insights from *Xenopus* may ultimately translate into therapeutic benefits in the form of new prospective diagnostic tests or chemotherapeutics. Although not the prototypical oncological model system, we propose that *Xenopus* is an adaptable and multifunctional tool in the oncologist׳s arsenal; a tool that compliments the more extensively used rodent models in cancer research.

Traditional approaches in rodent models have involved direct genetic manipulations, often resulting in the generation of mice harbouring oncogenic mutations or missing tumour suppressor genes or both (for instance [@bib11], [@bib50] but the list is endless). Alternatively, and sometimes complimentarily, tumours have been generated by chemical induction or through xenografted tumourigenic tissues, often from patient cancers (for review, see [@bib20]). These approaches have contributed to both the study of oncogenic mechanisms and also to provision of pre-clinical data prior to human trials.

Some advantages of these mammalian systems are obvious in terms of recapitulating the accumulation of multiple genetic mutations, complex tumour and stroma microenvironments, and immune regulation that are seen in human patients. However, mammalian models are not without their limitations in mimicking human disease, and indeed, the complexity of rodent models can itself hinder phenotypic analysis. For instance, cyclin-dependent kinases (cdks) play a central role in cell cycle progression, yet knock-out mouse models of even key cdks such as cdk2 and cdk4 result in a remarkably mild phenotype ([@bib12], [@bib80], [@bib85], [@bib101]). These highly unexpected findings have been shown to result from redundancy and/or facultative compensation between cdks ([@bib95]). Reduced complexity is one reason why *Xenopus* can triumph over rodents in such studies; for example, at early developmental stages studied, *Xenopus* has a single cdk inhibitor, p27Xic1, which has characteristics of all 3 mammalian Cip/Kip family cdkis ([@bib104], [@bib108]).

In cell division, differentiation and cancer, as in other areas, it is remarkable how almost all of what we see in *Xenopus* is recapitulated in mammalian cells and indeed *in vivo* in mice. This, once again, underscores the high degree of conservation of fundamental mechanisms amongst vertebrates, and it is clear that experiments in *Xenopus* can usually be undertaken on vastly shorter time-scales and at considerably smaller expense than those using mouse models. These facts, coupled with the animal welfare and ethical advantages of using eggs and tadpoles to replace rodents, means that *Xenopus* remains a vital and if somewhat underused weapon to provide initial observations that can then be extended into mammalian models of cancer. If scientists using *Xenopus* and mammalian models work together with a fuller understanding of the merits and drawbacks of both systems, our combined efforts will allow the maximum progress in the fight against cancer.
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![(A) A secondary axis can be induced in developing *Xenopus* embryos by injection of RNA encoding β-catenin into a ventral cell of 4-cell stage embryos. Ventral cells are usually distinguished by their larger size and darker pigment compared to dorsal cells. For detailed methods see ([@bib55]). (B) The duplicated axis is visible in neurula stage embryos within 2 days of injection. Embryos in these images have undergone *in situ* hybridisation for neural-β-tubulin to illustrate the bilateral stripes of primary neurons and trigeminal ganglia. Embryos can be exposed to a range of compounds during development to assay for ability of the compound to inhibit axis duplication. Alternatively, RNA encoding proteins of interest can be injected into the ventral cells to assay for ability of the protein to induce a secondary axis.](gr1){#f0005}
